M ycoplasma genitalium (MG) is a sexually transmitted infection (STI) and has recently been implicated in lower and upper reproductive tract disease in women and non-gonococcal urethritis in men. 1, 2 However, less is known about its prevalence and contribution to anorectal symptoms in men who have sex with men (MSM). Melbourne Sexual Health Centre (MSHC) has reported a significant increase in MG positivity in anal swabs from MSM, from 2.5% in 2009 to 12.7% in 2014 (P trend = 0.005), which was not the case for urine and urethral samples. 3 However, a limitation of that study was that the anal samples were from men regardless of symptoms, so it was not clear what proportion was from men who had symptoms of proctitis or from an asymptomatic contact of MG. A smaller MSHC study examining etiological agents of proctitis between 2012 and 2013 that included 21% HIV-positive men reported that 12% of cases had detectable MG 4 : however, the study did not provide information on the clinical presentation of MG proctitis compared with other etiological agents. A Ugandan study reported that the clinical presentation of urogenital MG may differ from other etiological agents, 5 but we are unaware of data on the clinical characteristics of MG-positive proctitis.
No STI guidelines recommend a treatment regimen specifically for MG-positive proctitis [6] [7] [8] with treatment based on current recommendations for urogenital MG infections. 9 Increasing macrolide resistance for urogenital MG is reported, and a recent meta-analysis of urogenital MG showed that the pooled cure for azithromycin in studies before 2009 12 and 61% (95% CI, 53-69) in 2012 to 2013. 13 These studies were dominated by urogenital MG with very few anorectal cases.
In this study, we report the clinical characteristics associated with proctitis in MSM attending MSHC between 2012 and 2016 in whom MG was detected and to compare this with the characteristics associated with the most established causes of proctitis, chlamydial, and gonococcal proctitis. We also compared the group of men who tested positive to MG and had other coinfections to examine the effect of MG alone (i.e., whether there were differences between MG monoinfection and MG coinfection). We report the proportions cured with first-line (azithromycin) and second-line antimicrobials (moxifloxacin, pristinamycin). To date, there has not been any published data for antimicrobials such as moxifloxacin and pristinamycin for management of anorectal MG, so we provide the first data for these 2 agents.
METHODS

Study Participants
We obtained routinely collected data from MSHC's electronic medical record database of patients diagnosed as having proctitis who were tested for all 3 pathogens (MG, Chlamydia trachomatis [CT], and Neisseria gonorrhoeae [NG] ) and had at least 1 detected. We included MSM 18 years and older who attended MSHC from June 2012 to May 2016. Men who have sex with men status was self-reported at registration as someone who ever had any oral or anal sex with another man. To avoid duplication of detecting persistent infection, we excluded men who presented with proctitis who had had the same organism detected within the previous 6 months. All cases included in the study were single episodes of proctitis.
Measurement
Demographic data were collected including patient's age, HIV serostatus, whether they had a current regular partner, the number of casual partners in the last 3 and 12 months, and any condomless receptive anal sex within the last 3 and 12 months. Clinical data collected included patient symptoms, the duration (anal pain, anal discharge, anal bleeding, anal itch, tenesmus), and clinical signs (inguinal lymphadenopathy, anal bleeding, discharge, and/or ulceration).
Proctitis was a clinical diagnosis made by the clinician, defined as anal pain with or without discharge and bleeding on examination. Proctoscopy was discretionary, performed in a subset of men (36%) in keeping with clinic practice because of poor tolerability in symptomatic patients and with increasing use of highly sensitive nucleic acid amplification testing where direct visualization and sampling from inflamed mucosa are not required. From June 2012, clinic guidelines recommended all men who presented to MSHC with proctitis have anal swabs to test for CT, NG, and MG. Testing for Treponema pallidum and herpes simplex virus (HSV) was performed at clinician's discretion. M. genitalium testing was performed at the Molecular Microbiology Laboratory at the Royal Women's Hospital using an in-house realtime polymerase chain reaction (PCR) assay targeting the 16s rRNA gene.
14 Before March 2015, chlamydia was detected using strand displacement amplification (BD Probetec) and gonorrhea was detected by culture on modified Thayer Martin medium. After March 2015, chlamydia and gonorrhea were detected using the APTIMA Combo 2 assay (GenProbe Diagnostics). 15 All positive gonorrhea results were confirmed using the Aptima GC test (Gen-Probe Diagnostics, San Diego, CA), 16 which uses a different nucleic acid target. When chlamydia was detected, genotyping for lymphogranuloma venereum (LGV) was performed using previously published methods with minor modifications. 17 The equivalent serovar was identified by finding the closest matching nucleotide sequence of L2 and L2b from GenBank Nos. M14738 and AY586530. Detection of HSV was by PCR targeting the glycoprotein B gene using conventional PCR and a real-time version of this.
18 T. pallidum was tested using a TaqMan real-time PCR assay. 19 
Statistical Analysis
We stratified the demographic and sexual behavior data by monoinfection with MG, chlamydia, or gonorrhea, and coinfection of MG with other STIs (this included NG, CT, LGV, HSV, and syphilis, and will henceforth be referred to as "MG coinfection"). We excluded from further analysis men who did not have rectal MG and had 2 or more other rectal STIs. To assess for statistically significant differences, we used Fisher exact test for categorical data and Kruskal-Wallis test for nonparametric continuous data. We conducted a multinomial multivariable logistic regression to test for significant differences between specific clinical features of proctitis caused by different etiological agents. The dependent variable was categorized into 4 different groups: MG monoinfection (reference group), chlamydial monoinfection, gonococcal monoinfection, and MG coinfection. This was adjusted for age, HIV status, and condomless receptive anal sex in the last 3 months. Prevalence odds ratios were calculated with the level of statistical significance at P < 0.05. Successful treatment outcomes were identified as men who had a repeat negative test result for MG at least 2 weeks after treatment with first line (azithromycin) or second line (moxifloxacin or pristinamycin) antimicrobials. Men were routinely recalled for their test of cure. All analyses were conducted using STATA software version 13.1 (StataCorp, College Station, TX).
Ethical approval was obtained from the Alfred Human Research Ethics Committee (308/16).
RESULTS
Study Population
During the study period, 201 MSM with 212 episodes of proctitis were tested for the 3 STIs: MG, CT, and NG. Cases were tested for anorectal herpes in 82% (174/212), anorectal syphilis using nucleic acid amplification testing in 57% (121/ 212), and of the men with anorectal chlamydia, 68% (54/80) were tested for anorectal LGV. The most prevalent agent detected in cases with symptoms of proctitis was gonorrhea (54% [95% CI, 47-61]), followed by chlamydia (38% [31-45]) and MG (31% [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] ). Lymphogranuloma venereum was detected in 4% (2/54) of men whose positive chlamydia anal swab was also tested for LGV strains.
For further analysis describing clinical features of proctitis, we excluded cases who had 2 or more other rectal STIs but no MG (n = 46). Therefore, we retained for analysis monoinfection cases with MG (17% [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] The demographic characteristics are summarized in Table 1 . Men with MG monoinfection had a higher median age (33 years) compared with those with MG coinfection (29 years), chlamydial monoinfection (27 years), and gonococcal monoinfection (25 years; P < 0.001). Men with MG monoinfection had less condomless receptive anal sex within the last 3 months (52%) compared with chlamydial monoinfection (88%), gonococcal monoinfection (71%), and MG coinfection (59%; P = 0.01). There was a higher proportion of HIV in men with MG monoinfection (28%) and MG coinfection (35%) compared with chlamydial monoinfection (12%) and gonococcal monoinfection (14%; P = 0.05). 
Clinical Characteristics of Anorectal MG
Treatment Outcomes
Most cases with MG returned for a test of cure (77%; 51/66). All cases who returned for a test of cure received azithromycin first line and the overall proportion with microbiological cure was low at 35% (95% CI, 22-50; 18/51). Thirteen cases had moxifloxacin as a second-line antimicrobial with an overall microbiological cure proportion of 92% (95% CI, 64-100; 12/13). Twenty-one cases received pristinamycin as a second-line antimicrobial with an overall microbiological cure of 79% (95% CI, 54-94; 15/19).
DISCUSSION
This study of MSM attending a sexual health center in Melbourne, Australia, investigated the clinical features of proctitis in which MG was detected and reported susceptibility to first-and second-line antimicrobials. It adds to the limited literature on anorectal MG infection by reporting that anorectal MG was as common as chlamydia in MSM presenting with symptoms of proctitis. However, MG proctitis was associated with fewer symptoms, indicative of lesser clinical severity of inflammation compared with cases of chlamydia or gonorrhea detected as the sole pathogen. Of concern but not unexpectedly, as with urethral infections, most MG-positive proctitis was not susceptible to macrolides. We contribute several important observations regarding anorectal MG in MSM. First, MG seems likely to be a causative agent of proctitis. It is possible that MG may be incidentally detected in men presenting with symptoms of proctitis because untreated urogenital MG may last for months or years. 20 However, against incidental detection is the fact that we found a significant difference in the anorectal MG prevalence between men with asymptomatic MG infection attending MSHC in another study compared with men with symptomatic MG. In an ongoing study at our service, 401 asymptomatic MSM were tested for anorectal MG and MG was detected in 5.0% (95% CI, 3.1-7.6). 21 In support of MG causing symptomatic anorectal infection, we found 6-fold higher positivity of anorectal MG amongst cases presenting with proctitis compared with this background prevalence in asymptomatic MSM. 21 Second, consistent with research in pelvic inflammatory disease (PID), 22 our findings suggest that MG may be less inflammatory compared with CT and NG, indicating that MG may be a more indolent infection in men and women. 23 Previous literature has been conflicting regarding the association between MG and symptomatic anorectal infection. This may be partly influenced by patient selection and the health-seeking patterns across populations. In a small study from the United States of 27 MSM with anorectal MG, investigators reported that rectal symptoms (rectal pain, bleeding, discharge, or tenesmus) were moderately associated with rectal MG detection (odds ratio, 2.8; 95% CI, 1.0-8.0). 24 However, they did not report the duration of symptoms or stratify their analysis according to specific symptoms. Conversely, in another small study from the UK of 19 MSM with anorectal MG, no associations were found between MG and symptoms of proctitis. 25 This difference may be either explained by their small sample size or that bacterial load of MG may influence symptoms for both urethral and anorectal MG. 4, 26 It is noteworthy that men presenting with symptomatic anorectal NG had higher bacterial loads compared with men with anorectal NG but without any rectal symptoms. 27 Not unexpectedly, most infections with MG proctitis were not susceptible to the first-line treatment of azithromycin. This is consistent with published evidence showing rising resistance in urogenital MG infections globally. 28 Furthermore, recent MSHC data in asymptomatic MSM confirm that 90% (95% CI, 68-99) of men with anorectal MG had macrolide resistance. 21 The overall cure of symptomatic anorectal MG with subsequent antimicrobials (moxifloxacin, pristinamycin) was consistent with the cure rates of 88% cure reported for moxifloxacin and 75% cure reported for pristinamycin found in urogenital MG. 13, 29 To the best of our knowledge, this is the first published data on the use of these agents for anorectal MG infection. These data indicate similar overall efficacy of the 3 antimicrobials for anorectal infection, as is reported for urogenital infection, but highlight the need for use of combined diagnostic resistance assays to facilitate selection of appropriate antimicrobials at the time of diagnosis and routine test of cure. 30 The strength of the study includes using a relatively large database of MSM with symptoms of proctitis, who were also comprehensively tested for other STIs. Most men returned for a test of cure for MG, enabling us to report the proportion of microbiological cure in men receiving various antimicrobials. This study should be read in light of some limitations. First, we did not perform proctoscopy in most cases, because this is an uncomfortable procedure of doubtful clinical value now that we have sensitive diagnostic tests that do not require direct visualization for collection. Second, gonococcal cases were predominantly culture positive and therefore likely to represent high bacterial load infections, which may bias our results toward more symptoms being associated with anorectal GC. Finally, we do not have contemporaneous data on the prevalence of MG in asymptomatic controls, which would enable us to establish an association between MG and proctitis, although an association seems likely from our recent asymptomatic prevalence study mentioned. 21 In conclusion, current international STI guidelines do not have clear recommendations for testing and treatment of MG in men presenting with proctitis. [6] [7] [8] This study found that MG was almost as common as chlamydia in men presenting to a sexual health center with symptoms of proctitis but seems to be associated with less marked symptoms than chlamydia and gonorrhea. These data are consistent with the evidence supporting the role of MG in PID, where it has taken many years to establish an association with PID. Symptom severity suggestive of anorectal inflammation seems to be very similar between the 3 STIs in PID and proctitis with MG seemingly the more indolent STI in both clinical syndromes. Based on the findings of this study, we recommend (i) testing for MG in men presenting with symptoms of proctitis, (ii) use of combined diagnostic-resistance assays to facilitate early selection of appropriate antimicrobials, and (iii) routine test of cure after antimicrobials. Cure after moxifloxacin and pristinamycin seems to be in line with that reported for urogenital MG. These data highlight the fact that MG is a relevant STI in MSM.
